drugset

drugset / Trial / NCT03639740

Treat-to-target With Secukinumab in Axial Spondyloarthritis

NCT03639740 ↗

Phase 4 Unknown 88 enrolled Professor Mikkel Østergaard Novartis Healthcare A/S · collab

SequentialOpen-labelTreatment

Summary

A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.

Timeline

Start: 2019-01-15
Primary completion: 2021-02
Completion: 2021-02

Publications

Vladimirova N, Ostergaard M, Seven S, Moller JM, Jensen B, Ostgard R, Poggenborg R, Madsen OR, Hendricks O, Brix L, Georgiadis S, Pedersen SJ. Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE). RMD Open. 2026 Apr 10;12(2):e006774. doi: 10.1136/rmdopen-2026-006774.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Secukinumab	Monoclonal antibody	300 mg	Subcutaneous

Indications